Type 2 Diabetes Mellitus Clinical Trial
— PHOTONOfficial title:
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema
| Verified date | May 2024 |
| Source | Regeneron Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks. The secondary objectives of the study are as follows: - To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response - To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept
| Status | Active, not recruiting |
| Enrollment | 660 |
| Est. completion date | June 29, 2024 |
| Est. primary completion date | May 30, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Key Inclusion Criteria: - Diabetic macular edema (DME) with central involvement in the study eye - Best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye with decreased vision determined to be primarily the result of DME - Willing and able to comply with clinic visits and study-related procedures - Provide informed consent signed by study participant or legally acceptable representative Extension Phase: All randomized patients that complete visit 26, week 96, as long as the patient 1) provides informed consent and 2) no treatment for DME has been given in the study eye other than the randomized study treatment. Key Exclusion Criteria: - Evidence of macular edema due to any cause other than diabetes mellitus in either eye - Active proliferative diabetic retinopathy in the study eye - IVT anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) or panretinal laser photocoagulation (PRP) /macular laser photocoagulation within 12 weeks (84 days) or intraocular or periocular corticosteroids within 16 weeks (112 days) of the screening visit in the study eye - Prior IVT investigational agents in either eye (eg, anti-ang-2/anti-VEGF bispecific monoclonal antibodies, gene therapy, etc.) at any time - Treatment with ocriplasmin (JETREA®) in the study eye at any time NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Regeneron Study Site | Calgary | Alberta |
| Canada | Regeneron Study Site | Mississauga | Ontario |
| Canada | Regeneron Study Site | North York | Ontario |
| Canada | Regeneron Study Site | Sherbrooke | Quebec |
| Czechia | Regeneron Study Site | Pardubice | |
| Czechia | Regeneron Study Site | Prague 5 | |
| Czechia | Regeneron Study Site | Praha 10 | |
| Czechia | Regeneron Study Site | Praha 2 | |
| Germany | Regeneron Study Site | Gottingen | Nordrhein-Westfalen |
| Germany | Regeneron Study Site | Munster | Nordrhein-Westfalen |
| Germany | Regeneron Study Site | Neubrandenburg | Mecklenburg-Westfalen |
| Hungary | Regeneron Study Site | Budapest | |
| Hungary | Regeneron Study Site | Budapest | |
| Hungary | Regeneron Study Site | Budapest | |
| Hungary | Regeneron Study Site | Budapest | |
| Hungary | Regeneron Study Site | Debrecen | |
| Hungary | Regeneron Study Site 1 | Pecs | Baranya |
| Hungary | Regeneron Study Site | Szeged | |
| Hungary | Regeneron Study Site | Szombathely | Vas |
| Hungary | Regeneron Study Site | Zalaegerszeg | Zala Megye |
| Japan | Regeneron Study Site | Chiyoda-ku | Tokyo |
| Japan | Regeneron Study Site | Fukuoka | |
| Japan | Regeneron Study Site | Fukuoka | |
| Japan | Regeneron Study Site | Hachioji | Tokyo |
| Japan | Regeneron Study Site | Hakodate | Hokkaido |
| Japan | Regeneron Study Site | Hirakata | Osaka |
| Japan | Regeneron Study Site | Itabashi-ku | Tokyo |
| Japan | Regeneron Study Site | Kagoshima | |
| Japan | Regeneron Study Site | Kashihara | Nara |
| Japan | Regeneron Study Site | Kawasaki | Kanagawa |
| Japan | Regeneron Study Site | Kita-gun | Kagawa |
| Japan | Regeneron Study Site | Kobe | Hyogo |
| Japan | Regeneron Study Site | Koriyama | Fukushima |
| Japan | Regeneron Study Site | Kurume | Fukuoka |
| Japan | Regeneron Study Site | Matsumoto | Nagano |
| Japan | Regeneron Study Site | Meguro-ku | Tokyo |
| Japan | Regeneron Study Site | Mito | Ibaraki |
| Japan | Regeneron Study Site | Nagakute | Aichi |
| Japan | Regeneron Study Site | Nagasaki City | Nagasaki |
| Japan | Regeneron Study Site | Nagoya | Aichi |
| Japan | Regeneron Study Site | Nagoya | Aichi |
| Japan | Regeneron Study Site | Osaka | |
| Japan | Regeneron Study Site | Saitama | |
| Japan | Regeneron Study Site | Shimotsuke-shi | Totigi |
| Japan | Regeneron Study Site | Susono | Shizuoka |
| Japan | Regeneron Study Site | Tokorozawa | Saitama |
| Japan | Regeneron Study Site | Tokushima | |
| Japan | Regeneron Study Site | Toride | Ibaraki |
| Japan | Regeneron Study Site | Tsuchiura-shi | Ibaraki |
| Japan | Regeneron Study Site | Ube | Yamaguchi |
| Japan | Regeneron Study Site | Yoshida-Gun | Fukui |
| Puerto Rico | Regeneron Study Site | Arecibo | |
| United Kingdom | Regeneron Study Site | London | |
| United Kingdom | Regeneron Study Site | Sunderland | Tyne And Wear |
| United States | Regeneron Study Site | 'Aiea | Hawaii |
| United States | Regeneron Study Site | Abilene | Texas |
| United States | Regeneron Study Site | Arcadia | California |
| United States | Regeneron Study Site | Asheville | North Carolina |
| United States | Regeneron Study Site | Augusta | Georgia |
| United States | Regeneron Study Site | Baltimore | Maryland |
| United States | Regeneron Study Site | Beachwood | Ohio |
| United States | Regeneron Study Site | Beaufort | South Carolina |
| United States | Regeneron Study Site | Bellaire | Texas |
| United States | Regeneron Study Site | Bethlehem | Pennsylvania |
| United States | Regeneron Study Site | Beverly Hills | California |
| United States | Regeneron Study Site | Bloomfield | New Jersey |
| United States | Regeneron Study Site | Boston | Massachusetts |
| United States | Regeneron Study Site | Campbell | California |
| United States | Regeneron Study Site | Carmel | Indiana |
| United States | Regeneron Study Site | Charlotte | North Carolina |
| United States | Regeneron Study Site | Cincinnati | Ohio |
| United States | Regeneron Study Site | Cincinnati | Ohio |
| United States | Regeneron Study Site | Clearwater | Florida |
| United States | Regeneron Study Site | Cleveland | Ohio |
| United States | Regeneron Study Site | Colorado Springs | Colorado |
| United States | Regeneron Study Site | Dublin | Ohio |
| United States | Regeneron Study Site | Durango | Colorado |
| United States | Regeneron Study Site | Edison | New Jersey |
| United States | Regeneron Study Site | Edmond | Oklahoma |
| United States | Regeneron Study Site | Encino | California |
| United States | Regeneron Study Site | Fairfax | Virginia |
| United States | Regeneron Study Site | Fort Lauderdale | Florida |
| United States | Regeneron Study Site | Fort Myers | Florida |
| United States | Regeneron Study Site | Fullerton | California |
| United States | Regeneron Study Site | Germantown | Tennessee |
| United States | Regeneron Study Site | Great Neck | New York |
| United States | Regeneron Study Site | Hagerstown | Maryland |
| United States | Regeneron Study Site | Henderson | Nevada |
| United States | Regeneron Study Site | Huntington Beach | California |
| United States | Regeneron Study Site | Jacksonville | Florida |
| United States | Regeneron Study Site | Kingston | Pennsylvania |
| United States | Regeneron Study Site | Knoxville | Tennessee |
| United States | Regeneron Study Site | Ladson | South Carolina |
| United States | Regeneron Study Site | Lakeland | Florida |
| United States | Regeneron Study Site | Lakewood | Colorado |
| United States | Regeneron Study Site | Largo | Florida |
| United States | Regeneron Study Site | Liverpool | New York |
| United States | Regeneron Study Site | Long Beach | California |
| United States | Regeneron Study Site 1 | Marietta | Georgia |
| United States | Regeneron Study Site 2 | Marietta | Georgia |
| United States | Regeneron Study Site | Melbourne | Florida |
| United States | Regeneron Study Site | Miami | Florida |
| United States | Regeneron Study Site | Monroeville | Pennsylvania |
| United States | Regeneron Study Site | Morgantown | West Virginia |
| United States | Regeneron Study Site | Nashville | Tennessee |
| United States | Regeneron Study Site | New York | New York |
| United States | Regeneron Study Site | Norfolk | Virginia |
| United States | Regeneron Study Site | Oak Forest | Illinois |
| United States | Regeneron Study Site | Oceanside | New York |
| United States | Regeneron Study Site | Orlando | Florida |
| United States | Regeneron Study Site | Palo Alto | California |
| United States | Regeneron Study Site | Pasadena | California |
| United States | Regeneron Study Site | Phoenix | Arizona |
| United States | Regeneron Study Site | Pinellas Park | Florida |
| United States | Regeneron Study Site | Plantation | Florida |
| United States | Regeneron Study Site | Portland | Oregon |
| United States | Regeneron Study Site | Poway | California |
| United States | Regeneron Study Site | Rancho Cordova | California |
| United States | Regeneron Study Site | Rapid City | South Dakota |
| United States | Regeneron Study Site | Riverside | California |
| United States | Regeneron Study Site | Royal Oak | Michigan |
| United States | Regeneron Study Site | Saint Petersburg | Florida |
| United States | Regeneron Study Site 1 | Salt Lake City | Utah |
| United States | Regeneron Study Site 2 | San Antonio | Texas |
| United States | Regeneron Study Site | Shawnee Mission | Kansas |
| United States | Regeneron Study Site | Shirley | New York |
| United States | Regeneron Study Site | Southaven | Mississippi |
| United States | Regeneron Study Site | Springfield | Illinois |
| United States | Regeneron Study Site | Springfield | Illinois |
| United States | Regeneron Study Site | Stuart | Florida |
| United States | Regeneron Study Site | Teaneck | New Jersey |
| United States | Regeneron Study Site | The Woodlands | Texas |
| United States | Regeneron Study Site | Torrance | California |
| United States | Regeneron Study Site | Tulsa | Oklahoma |
| United States | Regeneron Study Site | Waterford | Connecticut |
| United States | Regeneron Study Site | West Columbia | South Carolina |
| United States | Regeneron Study Site | Willow Park | Texas |
| United States | Regeneron Study Site | Winter Haven | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Regeneron Pharmaceuticals | Bayer |
United States, Canada, Czechia, Germany, Hungary, Japan, Puerto Rico, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). | Baseline, Week 48 | |
| Secondary | Percentage of Participants With a =2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48 | The DRSS was assessed according to the following scale: 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85. | Baseline, Week 48 | |
| Secondary | Percentage of Participants Gaining =15 Letters in BCVA From Baseline at Week 48 | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). Only one study eye per participant was analyzed within the study | Baseline, Week 48 | |
| Secondary | Percentage of Participants With BCVA =69 Letters at Week 48 | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). | At Week 48 | |
| Secondary | Percentage of Participants Without Fluid at Foveal Center at Week 48 | Retinal fluid status was evaluated using spectral domain optical coherence tomography (SD-OCT) on the study eye. | At Week 48 | |
| Secondary | Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48 | Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT). | Baseline, Week 48 | |
| Secondary | Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48 | Leakage is the release of fluorescein dye from diseased retinal vessels. | At Week 48 | |
| Secondary | Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48 | Vision-specific quality of life is assessed with the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire), i.e. a 25-item questionnaire that gives a score on a scale from 0 (worst) to 100 (best = no vision problems). | Baseline, Week 48 | |
| Secondary | Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48 | Concentrations of Free Aflibercept in Plasma by Time and Treatment Group | Through Week 48 | |
| Secondary | Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per Statistical Analysis Plan (SAP) Version 2.0 Appendix 10.9 for US Only) | Baseline, Week 48 | |
| Secondary | Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per SAP Version 2.0 Appendix 10.9 for US Only) | Baseline, Week 48 | |
| Secondary | Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60 | Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). | Baseline, Week 60 | |
| Secondary | Assessment of Immunogenicity to Aflibercept by Measuring the Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Through Week 96 | Number of participants with pre-existing immunoreactivity and treatment-emergent ADA response reported | Through Week 96 | |
| Secondary | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96 | A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent. | Through Week 96 | |
| Secondary | Number of Participants With Any Serious TEAE Through Week 96 | A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent. | Through Week 96 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|